MedPath

Methionine and Cysteine Restriction in Humans

Not Applicable
Completed
Conditions
Overweight
Interventions
Behavioral: Low met/cys diet
Behavioral: High met/cys diet
Behavioral: Moderate met/cys diet
Registration Number
NCT03629392
Lead Sponsor
University of Oslo
Brief Summary

The aim of this study is to examine the effect of methionine and cysteine restriction on energy and macronutrient metabolism in overweight human subjects

Detailed Description

The sulfur-containing amino acid methionine and its downstream metabolite cysteine has been associated with fat mass in animal studies and human observational studies. Some of the proposed mechanisms include an association with lipogenesis, insulin sensitivity and disrupted energy metabolism.

The overall aim of this project is to evaluate the effects of a diet low in methionine and cysteine on markers of lipids, amino acids, glucose and other biomarkers related to energy metabolism, including transcriptomic and protein expression data from adipose tissue and lymphocytes. Overweight and obese but otherwise healthy volunteers will be randomized to receive a diet either low, moderate or high in methionine and cysteine concentrations for 1 week.

This is a pilot study that may be considered an extension of NCT02647970. In addition to the primary and secondary outcomes we will evaluate the feasibility of the intervention and procedures.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
19
Inclusion Criteria
  • Body mass index of 25-35 kg/m2
Exclusion Criteria
  • High physical activity
  • Smoking
  • Drugs
  • Chronic disease
  • Pregnancy or breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Low met/cys dietLow met/cys dietDietary intervention
High met/cys dietHigh met/cys dietDietary intervention
Moderate met/cys dietModerate met/cys dietDietary intervention
Primary Outcome Measures
NameTimeMethod
Change in plasma concentrations of amino acidsBaseline, Day 1, Day 3 and Day 7 (final visit)

Measurement of biomarkers of amino acid metabolism, including plasma concentrations of methionine, cysteine and related metabolites

Change in protein expression activity in tissuesBaseline and day 7 (final visit for adipose tissue, Baseline and day 1, 3 and 7 (final visit) for lymphocytes.

Measurement of protein expression and activity related to methionine and cysteine metabolism in adipose tissue and lymphocytes.

Secondary Outcome Measures
NameTimeMethod
Change in plasma activity indices of steaoryl-CoA desaturaseBaseline, Day 1, Day 3 and Day 7 (final visit)

Calculated based onthe ratio of plasma concentrations of products and precursors

Change in protein expression of steaoryl CoA-desaturase in adipose tissueBaseline and Day 7 (final visit)

Measurement of protein expression of steaoryl CoA-desaturase in adipose tissue

Change in plasma concentrations of fatty acidsBaseline, Day 1, Day 3 and Day 7 (final visit)

Measurement of fatty acid content in plasma

Change in protein expression of steaoryl CoA-desaturase in lymphocytesBaseline, Day 1, Day 3 and Day 7 (final visit)

Measurement of protein expression of steaoryl CoA-desaturase in lymphocytes

Change in steaoryl CoA-desaturase activity in adipose tissueBaseline and Day 7 (final visit)

Measurement of enzyme activity of steaoryl CoA-desaturase in adipose tissue

Diet feasibilityBaseline, Day 1, Day 3 and Day 7 (final visit)

Diet feasibility will be measured by a self-administered questionnaire

Diet complianceBaseline, Day 1, Day 3 and Day 7 (final visit)

Compliance with the diet will be measured by a self-administered questionnaire

Body compositionBaseline and day 7 (final visit)

Measurement of body composition by bioimpedance and dual X-ray absorptometry

Trial Locations

Locations (1)

University of Oslo

🇳🇴

Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath